Publications
P302
Inorg. Chem., 2025, 64, 16192-16203.
Synthesis and Biological Evaluation of Itraconazole Derivatives: Design in an Old Scaffold.
https://doi.org/10.1021/acs.inorgchem.5c02730
P301
J. Med. Mycol. 2025, 101583.
A One Health Perspective on Diutina catenulata: Phenotypic Traits, Stress Sensitivity, and Virulence Across Diverse Isolates.
https://doi.org/10.1016/j.mycmed.2025.101583
P300
RSC Med. Chem. 2025, 16, 3746–3763.
Pharmacophore-guided optimization of the hit compound CTN1122 in the design of promising imidazo[1,2-a]pyrazine derivatives targeting the casein kinase 1 for antileishmanial therapy
https://doi.org/10.1039/D5MD00257E
P291
Mycoses. 2025, 68, e70085.
Clade Distinction and Tracking of Clonal Spread by Fourier-Transform Infrared Spectroscopy in Multicenter candida (Candidozyma) auris Ourbreak.
https://doi.org/10.1111/myc.70085
P290
ChemMedChem. 2025, 20, e202400862.
Investigating the C2 modulation of the imidazo[1,2-a]pyrazine-based hit compound CTN1122: synthesis, in vitro antileishmanial activity, cytotoxicity and casein kinase 1 inhibition.
https://doi.org/10.1002/cmdc.202400862
P286
J. Mycol. Med. 2024, 34, 101490.
Current knowledge and practice of Candida auris screening in France: A nationwide survey from the French Society of Medical Mycology (SFMM).
https://doi.org/10.1016/j.mycmed.2024.101490
P280
Chem. Biodiversity 2024, e202300563
Chemical Composition, Antifungal, Antioxidant, and Hemolytic Activities of Morrocan Thymus capitatus Essential Oil.
https://doi.org/10.1002/cbdv.202300563
P278
Antimicrob. Agents Chemother. 2024, e0002224.
Precise genome editing underlines the distinct contributions of mutations in ERG11, ERG3, MRR1, and TAC1 genes to antifungal resistance in Candida parapsilosis.
https://doi.org/10.1128/aac.00022-24
P275
Microorganisms 2023, 11, 2837.
Is the C-terminal domain an effective and selective target for the design of Hsp90 inhibitors against Candida yeast?
https://doi.org/10.3390/microorganisms11122837
P271
J. Med. Chem. 2023.
Discovery of new broad-spectrum anti-infectives for eukaryotic pathogens using boorganometallic chemistry.
https://doi.org/10.1021/acs.jmedchem.3c01333
P270
J. Fungi 2023, 9, 430.
The mortality attributable to candidemia in C. auris is higher than that in other Candida species: Myth or reality?
https://doi.org/10.3390/jof9040430
P268
Future Microbiol. 2023, 18, 1225-1233.
Antifungal efficacy of imidazo[1,2-a]pyrazine based thiosemicarbazones and thiazolidinediones against Sporothrix species.
https://doi.org/10.2217/fmb-2023-0044
P258
Future Microbiol. 2022, 17, 1437-1443.
Otomycosis caused by the cryptic and emerging species Aspergillus sydowii: two case reports.
https://doi.org/10.2217/fmb-2022-0137
P252
Clin. Microbiol. Infect. 2022.
Acquired fluconazole resistance and genetic clustering in Diutina (Candida) catenulata from clinical samples.
https://doi.org/10.1016/j.cmi.2022.09.021
P251
Microorganisms. 2022, 10, 938.
Prototheca infections and ecology from a One Health perspective.
https://doi.org/10.3390/microorganisms10050938
P249
PLoS One 2022.
CRISPR-Cas9 approach confirms Calcineurin-responsive zinc finger 1 (Crz1) transcription factor as a promising therapeutic target in echinocandin-resistant Candida glabrata.
https://doi.org/10.1371/journal.pone.0265777
P248
Rev. Iberoam. Micol. 2022.
Lethal destructive sinusopathy due to amphotericin B-resistant Aspergillus flavus: A case report.
https://doi.org/10.1016/j.riam.2022.01.001
P247
Int. J. Antimicrob. Agents. 2022.
Head-to-head comparison of CLSI, EUCAST, Etest and Vitek2 results for Candida auris susceptibility testing.
https://doi.org/10.1016/j.ijantimicag.2022.106558
P246
Microorganisms. 2022, 10, 104.
Impact of TR34/L98H, TR46/Y121F/T289A and TR53 alterations in azole‐resistant Aspergillus fumigatus on sterol composition and modifications after In Vitro exposure to itraconazole and voriconazole.
https://doi.org/10.3390/microorganisms10010104
P245
J. Antimicrob. Chemother. 2022, 77, 585–597.
Genotypic, proteomic, and phenotypic approaches to decipher the response to caspofungin and calcineurin inhibitors in clinical isolates of echinocandin-resistant Candida glabrata.
https://doi.org/10.1093/jac/dkab454
Autres publications scientifiques
PS07
Antimicrob. Agents Chemother. 2022, 66, e0156321.
Highly conserved gsc1 gene of Pneumocystis jirovecii in patients with or without prior exposure to ehinocandins.
https://doi.org/10.1128/AAC.01563-21
PS06
Parasite. 2022, 29.
Selecting a multiplex PCR panel for accurate molecular diagnosis of intestinal protists: a comparative study of Allplex® (Seegene®), G-DiaParaTrio (Diagenode®), and RIDA®GENE (R-Biopharm®) assays and microscopic examination.
https://doi.org/10.1051/parasite/2022003
Brevets
B18.
Multivalent fucose derivatives for use as a drug.
Demande de brevet européen n° 17 156 368.7 déposée le 15 février 2017.
B17.
Novel fused pyrimidone and triazinone derivatives containing bridged nitrogen, their process of preparation and their therapeutic uses as antifungal and/or antiparasitic agents.
PCT WO 2017/021178 A1, 9 février 2017.
B14.
Milieu, dispositif et procédé de test de la sensibilité d'un inoculum de champignons à un agent antifongique.
B10.
Composés en particulier de dérivés urées ou ester de l'acide haloacetamidobenzoïque et leur utilisation pour le traitement de maladies parasitaires.
Brevet européen n° 03 71 22 86 08, publié en 2006.
B9.
Antifungal and/or antiparasitic pharmaceutical composition and novel indole derivatives as active principle of such a composition.
Brevet US 2004067998 A1 publié le 8 avril 2004.
B8.
Antifungal and/or antiparasitic pharmaceutical composition and novel indole derivatives as active principle of such a composition.
Brevet CN 1473160A publié le 4 février 2004.
B7.
Procédé de détection de la sensibilité des levures aux antifongiques.
Brevet /FR 1 54 056 - A1 2003.
B6.
New azolyl-substituted indole derivatives and analogs, useful as antifungal and antiparasitic drugs effective e.g. against Candida albicans, Aspergillus fumigatus and Leishmania.
Brevet EP 1322638 publié le 2 juillet 2003.
B5.
Indole derivatives and their use as antifungal and/or antiparasitic agents.
Brevet CA 2 423 151 A1 publié le 21 mars 2003.
B3.
Activité antimicrotubulaire de nouveaux dérivés benzoylurées: activités antiparasitaires.
Fr. Pat. n° 02.01151, 31 Jan. 2002.
B2.
Antifungal and/or antiparasitic pharmaceutical composition and novel indole derivatives as active principle of such a composition.
Brevet PCT WO 02/24685 A1 déposé le 21 septembre 2001, publié le 28 mars 2002.
B1.
Composition pharmaceutique antifongique et/ou antiparasitaire et nouveaux dérivés de l'indole à titre de principes actifs d'une telle composition
Brevet FR 2 814 073 - A1 déposé le 21 septembre 2000, publié le 22 mars 2002.
Thèse